Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL437592 | 0.79 | TP53 (0.50) | POLBKMT2ARAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL4004484 | 0.77 | KMT2A (0.45) | POLBKMT2ARAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL2366245 | 0.77 | POLB (0.44) | POLBKMT2ARAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL20003160 | 0.77 | KMT2A (0.45) | POLBKMT2ARAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL246545 | 0.77 | POLB (0.73) | POLBKMT2ARAB9AALDH1A1LMNA | |
| SCHEMBL13875955 | 0.77 | POLB (0.44) | POLBKMT2ARAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL447082 | 0.77 | L3MBTL1 (0.51) | POLBKMT2ARAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL16408224 | 0.77 | RAB9A (0.48) | POLBKMT2ARAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL13890743 | 0.77 | GAA (0.46) | POLBKMT2ARAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL8184668 | 0.76 | MAPT (0.40) | KMT2ARAB9AL3MBTL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118255747-A | 3-Trifluoromethyl substituted pyrazole compound or pharmaceutically acceptable salt thereof and application thereof | 中山大学 | 2024-06-28 | — | — | CN | disclosed |
| WO-2023215367-A1 | BICYCLIC PIPERAZINONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| WO-2023066190-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022251561-A2 | SPIROINDOLINONE COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. SHAW RESEARCH, LLC (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| CN-110028442-B | Simple preparation method of Perampanel | 新发药业有限公司 | 2020-07-17 | — | — | CN | disclosed |
| US-20190321343-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-20 | — | — | US | disclosed |
| US-7718808-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20100029578-A1 | Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds | INTERMUNE, INC. | 2010-02-04 | — | — | US | disclosed |
| EP-1948178-A2 | METHODS OF TREATING ATRIAL FIBRILLATION WITH P38 INHIBITOR COMPOUNDS | Intermune, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| WO-2007053685-A2 | METHODS OF TREATING ATRIAL FIBRILLATION WITH P38 INHIBITOR COMPOUNDS | INTERMUNE, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20060270612-A1 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. | 2006-11-30 | — | — | US | disclosed |
| CN-1056840-C | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 2000-09-27 | — | — | CN | disclosed |
| CN-1143639-A | Oxime derivatives, their preparation and their therapeutic use | SANKYO CO (JP) | 1997-02-26 | — | — | CN | disclosed |
| US-4008086-A | PYRIDONE OR PYRIDAZONE DERIVATIVES | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JA) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321343-A1 | Anti-Fibrotic Pyridinones | MMP1, COL1A1, COL2A1 | POLB 1266/4885KMT2A 4574/4885RAB9A 2353/4885 |
| US-20100029578-A1 | Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds | ATF1, MAPKAPK3, MAPKAPK2 | POLB 4492/4885KMT2A 3709/4885RAB9A 1769/4885 |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | HCCS, HAVCR2, HDGF | POLB 395/4885KMT2A 545/4885RAB9A 443/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | POLB 3037/4885KMT2A 3885/4885RAB9A 2185/4885 |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ1, KCNC1 | POLB 4536/4885KMT2A 2130/4885RAB9A 1016/4885 |
| US-20060270612-A1 | Method of modulating stress-activated protein kinase system | MAPKAPK2, MAP3K6, MAP4K1 | POLB 3816/4885KMT2A 4406/4885RAB9A 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.